MR Imaging of Lymphadenopathy in Rectal Cancer using the MR Agent Vasovist

MR Imaging of Lymphadenopathy in Rectal Cancer using the MR Agent Vasovist - Vasovist in Rectal Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31454

Enrollment

Registered

2007-06-28

Start date

2008-07-12

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bowel cancer rectal cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Biopsy-proven rectal cancer Age: at least 18 years Surgery for rectal cancer planned within 60 days after Vasovist-enhanced MRI Willing and able to undergo all study procedures Written informed consent

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
Sensitivity, specificity, NPV and PPV of Vasovist®-enhanced MRI for detection lymph nodes with tumor infiltration (node-by node analysis)	—

Countries

Netherlands

Outcome results